Ck Life Sciences Int'L (Holdings) Inc.

CUSIP

G2176J105

SEDOL

N/A

CIK

N/A

www.ck-lifesciences.com

LEI:

New: Infographics X-Lab

Ck Life Sciences Int'L (Holdings) Inc.

BASIC = Free ADVANCED = User Account BUSINESS = Subscription PRIME = Subscription

ENTERPRISE = upon request

PROFILER

BASIC

ADVANCED

BUSINESS

PRIME

AI Insights

Ck Life Sciences Int'L (Holdings) Inc.

Click to initiate

ENTERPRISE

6.398,93 S&P · 17,93 Vola-Index · 118.849,21 BTC · 1,17419 EURUSD

Securities Trading

EQS Newswire is a major provider of regulatory and corporate news. It mainly serves companies, investors and media worldwide. Through its services, EQS Newswire enables efficient and secure communication between companies and their stakeholders. Its main services include the distribution of ad hoc announcements, corporate news and the publication of financial reports that meet strict international standards.

Tue, 22.04.2025

EQS Newswire / 22/04/2025 / 12:15 CET/CEST HONG KONG SAR - Media OutReach Newswire - 22 April 2025 - CK Life Sciences Int'l., (Holdings) Inc. ("the Company") announced that the Company will be presenting new data from its cancer vaccine research pipeline at the 2025 American Association for Cancer Research (AACR) Annual Meeting in Chicago, USA...

Research & Analysis

Fri, 11.04.2025

EQS Newswire / 11/04/2025 / 04:15 CET/CEST Breast Cancer Animal Studies Show Unprecedented Anti-Cancer Efficacy of 100% Tumor Growth InhibitionHONG KONG SAR - Media OutReach Newswire - 11 April 2025 - CK Life Sciences Int'l., (Holdings) Inc. ("CK Life Sciences"), a leader in cancer vaccine development, announces the latest progress in its phar...

Research & Analysis

We are different

OPEN FINANCIAL

DATA & KNOWLEDGE HUB

We make the difference

Information on product placements

BARRISTA SMART * AD

P R O D U C T S U G G E S T I O N S

Subject *

i.e Feature x is not working

Issue happened on *

This page

Other page

Page URL

Paste the page URL here

Bug Detail *

Please give us more detailed explanation of the issue

Steps to reproduce *

Specify the steps you've done before the issue happen

Actual Result *

What's the result of the issue?

Expected Result *

What do you expect to see?

Attachment

(Optional) You can send us a screenshot, word document, or a PDF explaining the issue

You have pressed the "". We would like to inform you that you are now leaving the information service of the portal site ayondo.com. You will be redirected to . After confirming the "Continue" button, you confirm that you have been informed of this. You also confirm that you are carrying out this process of your own free will and that it is not the result of any promotional activity or other influence. Continue to .

I would like to remain anonymous.

Subject *

e.g. New calculation method for Risk-of-Ruin-Calculator

View/Tool *

This view/tool

Another page/tool

Description of the proposed change/feedback *

The more comprehensible the description, the faster a feasibility check can be carried out.

General feedback on the view/tool/component/content *

Use this feedback text field for general or supplementary information

Would you use the tool and recommend it if necessary? *

Your opinion is valuable. Feel free to share it with us.

CK Life Sciences’ Investigational Cancer Vaccines Deliver Promising Results - New Preclinical Study Data to be Presented at the 2025 American Association for Cancer Research (AACR) Annual Meeting

CK Life Sciences Files Patent Applications for Circular mRNA TROP2 Cancer Vaccine

Newsletter